LigaChem Biosciences Inc. (KOSDAQ: 141080)

LigaChem Biosciences Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2019	Dec 31, 2018
Cash & Equivalents	153,644	63,054	117,965	139,940	66,888	10,221
Short-Term Investments	376,264	36,871	51,981	40,874	27,873	61,208
Cash & Short-Term Investments	529,908	99,925	169,946	180,814	94,762	71,429
Cash Growth	352.71%	-41.20%	-6.01%	90.81%	32.67%	207.69%
Accounts Receivable	11,689	14,809	12,780	22,457	11,120	17,667
Other Receivables	14,108	4,347	6,404	23,827	478.82	365.78
Receivables	25,797	19,156	19,184	46,284	11,699	18,033
Inventory	207.77	196.83	198.82	270.55	2,021	754.7
Prepaid Expenses	1,256	785.42	688.15	1,233	737.66	2,192
Other Current Assets	5,146	14,555	1,602	349.11	2,200	969.67
Total Current Assets	562,315	134,619	191,619	228,951	111,419	93,379
Property, Plant & Equipment	25,621	25,424	26,492	24,432	12,144	10,275
Long-Term Investments	24,327	17,340	19,825	22,631	7,326	5,185
Other Intangible Assets	6,870	6,901	7,889	8,601	8,988	10,110
Long-Term Deferred Tax Assets	981.89	981.16	-	-	-	-
Other Long-Term Assets	106,930	4,143	6,610	8,619	1,600	2,638
Total Assets	727,145	189,502	252,530	293,233	141,477	121,686
Accounts Payable	6,800	7,095	7,285	6,846	7,692	8,178
Accrued Expenses	1,371	11,268	3,764	417.57	364.32	135.74
Short-Term Debt	11,847	11,847	2,700	-	-	-
Current Portion of Long-Term Debt	-	-	9,147	2,700	-	-
Current Portion of Leases	465.29	268.56	185.81	158.2	111.18	-
Current Unearned Revenue	42.51	5.5	12.48	39.67	1,626	689.8
Other Current Liabilities	62,011	6,588	5,508	6,857	5,631	942.03
Total Current Liabilities	82,537	37,072	28,603	17,018	15,424	9,946
Long-Term Debt	-	-	-	9,147	1,900	-
Long-Term Leases	359.22	528.37	216.4	263.35	174	-
Long-Term Deferred Tax Liabilities	-	-	1,129	3,928	2,881	2,414
Other Long-Term Liabilities	383.08	316.02	378.15	468.07	1,267	970.79
Total Liabilities	89,837	41,281	32,932	34,459	25,568	16,392
Common Stock	18,284	14,060	12,752	12,117	5,361	5,295
Additional Paid-In Capital	568,310	97,523	93,881	349,792	185,180	184,479
Retained Earnings	42,297	30,740	105,383	-109,586	-78,812	-90,294
Treasury Stock	-4,879	-4,879	-	-	-	-
Comprehensive Income & Other	13,297	10,626	6,501	4,945	1,377	1,481
Total Common Equity	637,309	148,071	218,516	257,268	113,106	100,961
Minority Interest	-	-	-	-	2,160	3,630
Shareholders' Equity	637,309	148,221	219,599	258,775	115,909	105,295
Total Liabilities & Equity	727,145	189,502	252,530	293,233	141,477	121,686
Total Debt	12,672	12,644	12,249	12,269	2,185	-
Net Cash (Debt)	517,237	87,281	157,697	168,545	92,576	71,429
Net Cash Growth	393.15%	-44.65%	-6.44%	82.06%	29.61%	793.74%
Net Cash Per Share	15235.72	3072.85	5628.72	6986.35	3855.44	3389.28
Filing Date Shares Outstanding	36.43	27.98	25.5	24.23	21.44	21.18
Total Common Shares Outstanding	36.43	27.98	25.5	24.23	21.44	21.18
Working Capital	479,778	97,547	163,016	211,933	95,995	83,433
Book Value Per Share	17495.34	5291.96	8568.24	10615.60	5274.52	4766.84
Tangible Book Value	630,439	141,169	210,627	248,667	104,118	90,851
Tangible Book Value Per Share	17306.75	5045.31	8258.90	10260.69	4855.36	4289.52
Land	2,815	2,815	2,815	2,815	2,591	2,591
Buildings	16,184	16,134	16,119	16,104	2,559	2,559
Machinery	746.33	13,824	13,135	9,060	9,779	7,702
Construction In Progress	6.36	-	184.65	174	2,577	1,441

Source: S&P Capital IQ. Standard template. Financial Sources.